The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia
Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. crisugabalin, a new highly selective 2 ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or crisugabalin in treating FM, with the aim of providing a better treatment option for FM patients.
Phase:
NA
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborators:
China-Japan Friendship Hospital Peking University Third Hospital The Affiliated Hospital of Yanbian University The First Affiliated Hospital of Nanchang University The Fourth Affiliated Hospital of Harbin Medical University Xiangya Hospital of Central South University Zhongnan Hospital